Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring ST-Elevation Myocardial Infarction
Eligibility Criteria
Inclusion Criteria: Ischemic chest discomfort of 30 minutes duration Onset of chest pain 12 hours prior to entry into the study ST segment elevation of > 1 mm (0.1 mV) in two or more contiguous electrocardiographic leads (on a standard 12 lead electrocardiogram [ECG]), or left bundle branch block not known to be old Exclusion Criteria: Active bleeding History of stroke within 90 days or any intracranial bleed. Major surgery or trauma within the past 6 weeks Uncontrolled hypertension (systolic blood pressure [SBP] 200 mm Hg and/or diastolic blood pressure [DBP] 110 mm Hg despite treatment) Prolonged (> 10 minutes) cardiopulmonary resuscitation Inadequate vascular access PCI within the last 30 days Thrombolytic agents within the preceding 7 days Concurrent use of warfarin A blood coagulation disorder (i.e. international normalized ratio [INR] > 2.0, platelet count < 100,000/mm3, or hematocrit < 30%) Intolerance to aspirin or clopidogrel A subcutaneous therapeutic dose of any low molecular weight heparin (LMWH) within 12 hours Known severe contrast allergy Other medical condition that is likely to result in death within 12 months Participation in a study or another investigational device or drug trial within the past four weeks Pregnancy Known severe renal impairment (creatinine > 200 mole/l) Sustained hypotension, systolic blood pressure < 80 mm Hg, or the need for intravenous (IV) inotropes and/or intraaortic balloon counterpulsation to support the blood pressure Inability to provide informed consent
Sites / Locations
- University of Ottawa Heart Institute